RZLT shares plummet 90% after Phase 3 trial failure. Hagens Berman investigates. Dec. 11, 2025.
In San Francisco on December 30, 2025, Rezolute, Inc. (NASDAQ: RZLT) experienced a significant drop in share price, plummeting by as much as 90% on December 11, 2025. This sudden decline came following the announcement of the unsuccessful Phase 3 sunRIZE trial results for ersodetug (known as "erso"). The company faced challenges as investors grappled with the news, marking a substantial setback in the company's journey.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments